Impact of an oral nutritional supplement on the body composition of older adults with or at risk of malnutrition in an institutionalised setting: A randomised controlled trial.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

Who Took Part

The abstract describes 50 participants taking part.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

An open-label randomised controlled, parallel-group study was conducted among older adults (age ≥ 60 years) with/at risk of malnutrition (mini nutrition assessment-short form score ≤ 11).

In total, 50 participants were randomly assigned to the intervention (IG) and control (CG) groups (1:1 ratio).

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Being open-label, the Copper (Supplement) study did not mask who received what.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Anthropometric measurements, body composition analysis, and dietary and physical activity assessments were performed at the beginning and end of the study.

What Was Measured

The subject headings attached to it are Body Composition, Dietary Supplements, Malnutrition, Nutrition Assessment, Nutritional Status and Institutionalization.

The authors tagged it with the keywords ONS, body weight, older adults and oral nutritional supplement.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Copper (Supplement) in 50 participants.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Journal of human nutrition and dietetics : the official journal of the British Dietetic Association), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.